- Home
- WFG vs LEGN Comparison
WFG vs LEGN Comparison
Compare WFG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | LEGN |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WFG | LEGN |
|---|---|---|
| Price | $59.69 | $21.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $93.00 | $69.58 |
| AVG Volume (30 Days) | 268.2K | ★ 2.6M |
| Earning Date | 10-22-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,702,000,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.83 |
| Revenue Next Year | $9.45 | $51.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $57.34 | $21.19 |
| 52 Week High | $93.03 | $45.30 |
Technical Indicators
Market Signals| Indicator | WFG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 25.47 |
| Support Level | $59.30 | $21.19 |
| Resistance Level | $62.57 | $28.97 |
| Average True Range (ATR) | 1.63 | 1.27 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 1.36 | 9.13 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.